1. A method of treating a stroke in a mammalian individual, comprising the steps of (a) initiating the administration of a G-CSF or a functionally active derivative of G-CSF to the individual in a therapeutically active amount, and subsequently (b) administering to the individual a thrombolytic agent in a therapeutically active amount. The method according to claim 1, wherein the individual undergoes a diagnostic examination after stage (a) and before stage (b) to eliminate the risk of hemorrhage or other adverse side effects during stage (b). The method of claim 1 or 2, wherein the human G-CSF is used for step (a). The method of claim 1, wherein rt-PA is used for step (b). The method according to claim 1, where the introduction of G-CSF or a functionally active derivative of G-CSF begins within the first 6 hours after the onset of stroke. The method according to claim 1, wherein the thrombolytic agent is administered later than 6 hours after the onset of the stroke. The method according to claim 1, where the introduction of G-CSF or a functionally active derivative of G-CSF ends within the first 6 hours after the onset of stroke. The method of claim 1, wherein the thrombolytic agent is administered at least 0.5 hours after the start of administration of G-CSF or a functionally active derivative of G-CSF. The method according to claim 2, where the diagnostic examination lasts at least 0.5 hours 10. The method of claim 1, wherein the G-CSF is administered intravenously or subcutaneously at a dose of at least 90 μg / kg body weight. The use of G-CSF or a functionally active derivative of G-CSF for the preparation of a pharmaceutical composition for treating a mammal of an individual suffering from an acute stroke, where the individual is delivered to the department or clinic for the treatment of stroke within the first 6 hours after the onset of the stroke, and where time is spent on diagnostic examination1. Способ лечения инсульта млекопитающего индивида, включающий
